Form 4 Mylan N.V. For: Feb 05 Filed by: Campbell Paul

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. TISI
10. BHP

Go back to Form 4 Mylan N.V. For: Feb 05 Filed by: Campbell Paul

Mylan (MYL) Misses Q4 EPS by 5c

February 10, 2016 4:13 PM EST

Mylan (NASDAQ: MYL) reported Q4 EPS of $1.22, $0.05 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.7 billion.

GUIDANCE:

Mylan sees FY2016 EPS of $4.85-$5.15, versus the consensus of $4.90.

For earnings history and earnings-related data on Mylan (MYL) click here.

... More

Mylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B Deal

February 10, 2016 4:03 PM EST

Price of SEK 165 per Meda Share at Announcement Represents a Multiple of Approximately 12.9x 2015 Adjusted EBITDA and 8.9x 2015 Adjusted EBITDA with Synergies

Strengthens Mylan's Position as a Diversified Global Pharmaceutical Leader with an Expansive and Growing Portfolio of Specialty, Generic and OTC Products and a Strong, Complementary Therapeutic Presence

Combined Business Will Have Critical Mass across Commercial Channels in Europe, a Leading U.S. Specialty Business, and an Exciting Platform for Growth in Emerging Markets

Expected to Be Immediately Accretive to Mylan Earnings, with Accretion Increasing Significantly after First Full Year (2017) as Synergies Are Realized; Creates... More